News Home

Is Chimerix Inc (CMRX) a Good Buy in the Biotechnology Industry?

Thursday, August 18, 2022 10:08 AM | InvestorsObserver Analysts

Mentioned in this article

Is Chimerix Inc (CMRX) a Good Buy in the Biotechnology Industry?

A rating of 44 puts Chimerix Inc (CMRX) near the middle of the Biotechnology industry according to InvestorsObserver. Chimerix Inc's score of 44 means it scores higher than 44% of stocks in the industry. Chimerix Inc also received an overall rating of 48, putting it above 48% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Overall Score - 48
CMRX has an Overall Score of 48. Find out what this means to you and get the rest of the rankings on CMRX!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 48 would rank higher than 48 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Chimerix Inc Stock Today?

Chimerix Inc (CMRX) stock is trading at $2.52 as of 10:08 AM on Thursday, Aug 18, a decline of -$0.03, or -1.37% from the previous closing price of $2.55. The stock has traded between $2.48 and $2.58 so far today. Volume today is below average. So far 284,965 shares have traded compared to average volume of 6,174,143 shares. Click Here to get the full Stock Report for Chimerix Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App